158 related articles for article (PubMed ID: 35089801)
21. The cysteinyl leukotriene 2 receptor mediates retinal edema and pathological neovascularization in a murine model of oxygen-induced retinopathy.
Barajas-Espinosa A; Ni NC; Yan D; Zarini S; Murphy RC; Funk CD
FASEB J; 2012 Mar; 26(3):1100-9. PubMed ID: 22131271
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 Oxidase 2C Inhibition Adds to ω-3 Long-Chain Polyunsaturated Fatty Acids Protection Against Retinal and Choroidal Neovascularization.
Gong Y; Fu Z; Edin ML; Liu CH; Wang Z; Shao Z; Fredrick TW; Saba NJ; Morss PC; Burnim SB; Meng SS; Lih FB; Lee KS; Moran EP; SanGiovanni JP; Hellström A; Hammock BD; Zeldin DC; Smith LE
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1919-27. PubMed ID: 27417579
[TBL] [Abstract][Full Text] [Related]
23. Technology evaluation: pegaptanib, Eyetech/Pfizer.
Vinores SA
Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy.
Cao R; Jensen LD; Söll I; Hauptmann G; Cao Y
PLoS One; 2008 Jul; 3(7):e2748. PubMed ID: 18648503
[TBL] [Abstract][Full Text] [Related]
25. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
26. Novel targets against retinal angiogenesis in diabetic retinopathy.
Wang S; Park JK; Duh EJ
Curr Diab Rep; 2012 Aug; 12(4):355-63. PubMed ID: 22638940
[TBL] [Abstract][Full Text] [Related]
27. microRNA-181a inhibits ocular neovascularization by interfering with vascular endothelial growth factor expression.
Yang C; Tahiri H; Cai C; Gu M; Gagnon C; Hardy P
Cardiovasc Ther; 2018 Jun; 36(3):e12329. PubMed ID: 29608244
[TBL] [Abstract][Full Text] [Related]
28. Thrombospondin-1-Based Antiangiogenic Therapy.
Sims JN; Lawler J
J Ocul Pharmacol Ther; 2015 Sep; 31(7):366-70. PubMed ID: 26352160
[TBL] [Abstract][Full Text] [Related]
29. Novel Peptide NT/K-CRS Derived from Kringle Structure of Neurotrypsin Inhibits Neovascularization
Yao X; Chen C; Zhang J; Xu Y; Xiong S; Gu Q; Xu X; Suo Y
J Ocul Pharmacol Ther; 2021 Sep; 37(7):412-420. PubMed ID: 34252290
[No Abstract] [Full Text] [Related]
30. A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.
Palmer GM; Tiran Z; Zhou Z; Capozzi ME; Park W; Coletta C; Pyriochou A; Kliger Y; Levy O; Borukhov I; Dewhirst MW; Rotman G; Penn JS; Papapetropoulos A
Br J Pharmacol; 2012 Mar; 165(6):1891-1903. PubMed ID: 21943108
[TBL] [Abstract][Full Text] [Related]
31. Gaining insight on mitigation of rubeosis iridis by UPARANT in a mouse model associated with proliferative retinopathy.
Locri F; Pesce NA; Aronsson M; Cammalleri M; De Rosa M; Pavone V; Bagnoli P; Kvanta A; Dal Monte M; André H
J Mol Med (Berl); 2020 Nov; 98(11):1629-1638. PubMed ID: 32940719
[TBL] [Abstract][Full Text] [Related]
32. 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours.
Butler CT; Kennedy SA; Buckley A; Doyle R; Conroy E; Gallagher WM; O'Sullivan J; Kennedy BN
Oncotarget; 2019 Jun; 10(38):3725-3744. PubMed ID: 31217905
[TBL] [Abstract][Full Text] [Related]
33. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP
Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic therapy for ischemic retinopathies.
Al-Latayfeh M; Silva PS; Sun JK; Aiello LP
Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a006411. PubMed ID: 22675660
[TBL] [Abstract][Full Text] [Related]
35. SCF (Stem Cell Factor) and cKIT Modulate Pathological Ocular Neovascularization.
Kim KL; Seo S; Kim JT; Kim J; Kim W; Yeo Y; Sung JH; Park SG; Suh W
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2120-2131. PubMed ID: 31434494
[TBL] [Abstract][Full Text] [Related]
36. Vasoinhibins: novel inhibitors of ocular angiogenesis.
Clapp C; Thebault S; Arnold E; García C; Rivera JC; de la Escalera GM
Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E772-8. PubMed ID: 18544641
[TBL] [Abstract][Full Text] [Related]
37. Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye.
Santonocito M; Zappulla C; Viola S; La Rosa LR; Solfato E; Abbate I; Tarallo V; Apicella I; Platania CBM; Maugeri G; D'Agata V; Bucolo C; De Falco S; Mazzone MG; Giuliano F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922399
[TBL] [Abstract][Full Text] [Related]
38. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
39. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
40. An arylidene-thiazolidinedione derivative, GPU-4, without PPARγ activation, reduces retinal neovascularization.
Nakamura S; Hayashi K; Takizawa H; Murase T; Tsuruma K; Shimazawa M; Kakuta H; Nagasawa H; Hara H
Curr Neurovasc Res; 2011 Feb; 8(1):25-34. PubMed ID: 21208163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
